ID   FM57
AC   CVCL_C594
SY   FM-57
DR   cancercelllines; CVCL_C594
DR   Cosmic; 808546
DR   Cosmic; 874439
DR   Cosmic; 1047668
DR   Cosmic; 2163770
DR   ECACC; 13012418
DR   ESTDAB; ESTDAB-017
DR   GEO; GSM156034
DR   IARC_TP53; 26095
DR   Progenetix; CVCL_C594
DR   Wikidata; Q54835051
RX   PubMed=7656272;
RX   PubMed=8968104;
RX   PubMed=9688544;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*02:01; B*07:02,51:01:01; C*07:02,15:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01,15:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
ST   Source(s): ECACC=13012418; ESTDAB=ESTDAB-017
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,9 (ESTDAB=ESTDAB-017)
ST   D13S317: 12 (ECACC=13012418)
ST   D16S539: 11,12
ST   D3S1358: 15,17
ST   D5S818: 12,13 (ESTDAB=ESTDAB-017)
ST   D5S818: 13 (ECACC=13012418)
ST   D7S820: 8,10
ST   FGA: 22,23
ST   TH01: 7,10
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 20
//
RX   PubMed=7656272; DOI=10.1007/BF01527402; PMCID=PMC11037630;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=9688544; DOI=10.1016/S0014-5793(98)00603-6;
RA   Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated
RT   human melanomas.";
RL   FEBS Lett. 430:227-230(1998).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//